β受体阻滞剂治疗婴幼儿血管瘤的研究

Study onβ-blockers in the Treatment of Infantile Hemangioma

婴幼儿血管瘤(IH)是一种常见的良性肿瘤,一般发生于婴幼儿的颌面部位,大部分可以自行消退,但有少部分患儿不能完全自愈。对于面积较大、进行性扩展、发生在颌面部影响美观且危险性较高的IH患者,仍主张早期干预。目前,IH的临床治疗药物主要以β受体阻滞剂为主,其可收缩血管、缩小瘤体体积,诱导并加速细胞凋亡,促进血管瘤消退。本文就IH的分类和风险评估、β受体阻滞剂药物治疗IH的机制及给药途径作一综述,旨在为临床治疗IH提供参考依据。

Infantile hemangioma(IH)is a common benign tumor that usually occurs in the maxillofacial region of infants and young children.Most of them can resolve on their own,but a small number of children cannot completely heal themselves.Early intervention is still recommended for patients with IH who are large in area,progressively expand,and have a beautiful and dangerous effect on the maxillofacial region.At present,β-blockers are mainly used in clinical treatment of IH,which can shrink blood vessels,reduce tumor volume,induce and accelerate apoptosis,and promote hemangioma regression.This article reviews the classification and risk assessment of IH,the mechanism and route of administration ofβ-blocker drugs for IH,and aims to provide a reference for clinical treatment of IH.